Clinical Perspectives

Dendritic Cell Vaccine Shows Promising Results in Multiple Myeloma Patients

A new dendritic cell vaccine has shown promising results in treating high-risk multiple myeloma patients. 

Neurological Complications and Treatment Options from Immunotherapy Side Effects

The peripheral and central nervous systems are sometimes affected by immunotherapy treatment. Learn more about how Moffitt is treating this side...

Advancing the Standard of Care for Breast Cancer Patients with Magseed® and Magtrace® Technology

The Breast Oncology Program is an early adopter of the pioneering technology of Magseed and Magtrace.

Moffitt’s CDH1 Clinic Brings Expert Knowledge and Care to Reduce the Risk of Hereditary Diffuse Gastric Cancer

The CDH1 clinic coordinates multidisciplinary care between the Genetics, Gastroenterology and the Breast departments.

FDA Approves Luspatercept for First-Line Treatment of Myelodysplastic Syndromes

Luspatercept, TGF-b ligand fusion trap protein, which stimulates terminal erythroid differentiation to enhance red blood cell production was approved...

Dr. Robert Wenham Discusses Advancements in the Treatment of Gynecologic Cancers

Dr. Robert Wenham, chair of the Gynecologic Oncology Program at Moffitt, leads a multidisciplinary team, leveraging the latest advances in treatment.

4 CAR T Myths for Lymphoma Patients

Moffitt is an established leader in the field of bone marrow transplantation (BMT) and chimeric antigen receptor or CAR T cell therapy.

Tumor Infiltrating Lymphocyte Therapy (TIL) has Shown Promise in Melanoma Treatment

Moffitt is at the forefront of Tumor infiltrating lymphocyte therapy (TIL), a cellular therapy to treat melanoma and other solid tumors.

The Moffitt Difference: Comprehensive Cancer Care

By embracing a holistic approach, Moffitt prioritizes the whole patient throughout their cancer journey.

Radiation Therapy for Benign Diseases

A large number of cancer patients receive radiation therapy at some point during their course of treatment, but radiation therapy may also be...

New Moffitt McKinley Hospital to Feature Intraoperative Magnetic Resonance Imaging

Moffitt McKinley Hospital will be home to a state-of-the-art intraoperative magnetic resonance imaging (iMRI) system to assist surgeons during...

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Fred Locke of the Department of Blood and Marrow Transplant and Cellular Immunotherapy Program details survival with Axicabtagene Ciloleucel in Large...

Cell Therapies and Exercise

Moffitt is are exploring how combining complex cell therapies with novel and holistic recovery strategies to facilitate recovery can help optimize...

5 Myths vs Facts About CAR T for Myeloma

Moffitt is an established leader in the field of bone marrow transplantation (BMT) and chimeric antigen receptor or CAR T cell therapy.

Evaluating TMB Compared to tDNA TMB in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

High tumor mutation burden (TMB) is connected to immune checkpoint inhibitor (ICI) response in many solid tumors.